Immaterial Misstatements News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead candidate by Janssen Biotech and IND clearance for SGN-EGFRd2 (LAVA-1223) by SeagenPortfolio reprioritization and extension of cash runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody

(2023-08-22 | NDAQ:LVTX) LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Lead development candidate selected by Janssen Biotech under research collaboration provides a milestone payment to LAVAStrong balance sheet expected to provide cash runway into 2026 UTRECHT, The... | June 8, 2023

Table of Contents Exhibit 99.1 LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED... | June 8, 2023

13.09.2022 - Initial Phase 1/2a clinical findings for LAVA-051 in patients with chronic lymphocytic leukemia and multiple myeloma patients demonstrated encouraging anti-tumor activity and safety profile; on track to report additional clinical data in fourth ...